Studies of the three human creatine phosphokinase (EC 2.7.3.2) isoenzymes, MM, MB, and BB,
Creatine phosphokinase (CPK EC 2.7.3.2) which exists in multiple forms is a dimer composed of either muscle (M) or brain (B) type subunits. The CPK isoenzymes differ in amino acid composition, catalytic constants, and electrophoretic mobility (1-3). Consequently, it is possible to determine the isoenzyme content of a sample by electrophoretic separation (4) . This method is reasonably sensitive but timeconsuming. It was desirable to have a rapid and quantitative assay for the isoenzymes which does not require electrophoresis.
Eppenberger et al. demonstrated that the MM and BB isoenzymes from both rabbits and chickens exhibited different kinetic properties (2) . In the reaction CP + ADP -± creatine + ATP, Km values were found to be lower for both ADP and creatine phosphate (CP) with the BB isoenzyme. When creatine phosphate was present in excess the BB isoenzyme was inhibited more than the MM isoenzyme. When reaction rates were compared at high versus low substrate concentrations, different ratios of activity for the three isoenzymes were observed. Similar observations were reported by Dawson and Fine (5) with the CPK isoenzymes from human tissue.
Since brain contains only the BB type enzyme and skeletal muscle has virtually 100% MM type, while human myocardial tissue contains 70% MM and 30% MB (6) , the appearance of MB enzyme in the serum is useful for diagnosing myocardial damage. Normal human serum contains only the MM isoenzyme while the MB enzyme appears in serum from patients after an acute myocardial infarction (7) (8) (9) . In the present study we have utilized known differences in the kinetic properties of the isoenzymes to detect the MB isoenzyme in serum from such patients with a new procedure not requiring electrophoresis.
The method conventionally used for the detection of CPK activity in sera is that of Rosalki (10) and is a coupled enzyme assay. However, this assay cannot be used at very low concentrations of substrates due to a lack of sensitivity. Since we wished to assay CPK at very low substrate concentrations where the difference in activity of the isoenzymes is most apparent, we developed a kinetic method in which the ATP produced is measured by the firefly light-emitting reaction. Thus the reaction CP + ADP = creatine + ATP is followed by coupling the ATP formed with the firefly luciferase reaction in which E ATP + luciferin + 02 --oxyluciferin + AMP + PPi + CO2 + h., where E is luciferase.
Under selected conditions the light emission at any moment is proportional to the amount of ATP present at that instant.
When CPK is present in the reaction medium, and its substrates, ADP and CP, are added, the rate of increase of emission of light is proportional to the rate of formation of ATP during a measured interval. By using the Rosalki method for CPK activity at high substrate concentrations and the luciferase-coupled assay at low substrate concentrations, it is possible to determine the amount of the three isoenzymes present in a sample. We have used this technique to study the changes in serum CPK isoenzymes in patients with acute myocardial infarction. The data indicate that this is a rapid and sensitive method for detecting the appearance of MB isoenzyme in serum.
MATERIALS AND METHODS
Reagents. Total CPK activity was assayed according to Rosalki (10) glucose-6-P + ADP glucose-6-P glucose-6-P + NADP ed n dehydrogenase 6-phosphogluconate + NADPH The rate of appearance of NADPH was followed by the change in optical density at 340 nm and is proportional to the CPK activity after 7 min. In this assay the final concentration of ADP was 18 mM and CP was 1.2 mM. CPK activity was expressed in international units, IU/ml.
The luciferase-coupled assay was measured by light emission in an Aminco-Chemglo photometer. The emission of light as a function of time was recorded on a Beckman recorder. The reaction medium contained 0.025 M Tris-HCl buffer, pH 7.8; 0.1 mM luciferin; 0.012 mg of luciferase (6000 light units as determined by flash height); 5 mM MgSO4; 2 mM 2-mercaptoethanol in a total volume of 0.4 ml. To start the reaction 20 Ml of an ADP solution and 20,ul of the CPK sample were added and the baseline light emission was recorded. If there was myokinase present in the sample, light emission was observed before the addition of CP. This background light emission was subtracted from the final light emission observed upon the addition of CP. The light output was measured for 15 see and was linear over this period. A typical CPK-luciferase assay is shown in Fig. 1 this disparity further. When samples of MM and BB that had the same activity in the Rosalki assay (0.05 IU/ml) were assayed at low substrate concentrations with the luciferase system, BB isoenzyme exhibited a 4 times higher activity than MM. MB exhibited intermediate activity under these conditions. This relationship held over a wide range of enzyme activity. Assays of CPK activity using the Rosalki method are linear over a range of 0-0.130 IU/ml, while the luciferase assay linearity is observed over 0-2.0 IU/ml.
Mixtures of BB and MM or of MB and MM were prepared, with each mixture containing the same total CPK activity measured spectrophotometrically. When these mixtures were assayed at low substrate concentration with the bioluminescence system, a linear relationship between the percentages of each isoenzyme and the measured activity was found (Fig. 4) . After having established this relationship we examined CPK activity in samples of human sera at low and high substrate concentrations.
Serum samples were obtained from normal subjects and from patients with an elevated CPK activity due to an acute myocardial infarction. Normal serum samples always showed a ratio of enzyme activities at high and low substrate concentrations that was the same as that which would have been observed if all the serum CPK were MM CPK. Sera from patients with acute myocardial infarctions showed increased activities when assayed at low substrate concentrations, as compared to spectrophotometric CPK activity, an observation indicative of the appearance of the MB isoenzyme in serum. This appeatance of MB was confirmed by electrophoresis. With the use of a standard curve (Fig. 4) the percentage of MB CPK appearing in the blood could be determined. In order to obtain the time course of disappearance of MB CPK activity, serial serum samples from a patient with an acute myocardial infarction were assayed for total CPK spectrophotometrically and for MB CPK by bioluminescence. Total CPK and MB CPK initially increased in a parallel fashion. MB activity declined faster, however, probably reflecting a higher degradation rate (Fig. 5 ).
DISCUSSION
The fact that creatine phosphokinase exists in different forms depending whether its subunits are M or B has led to investigations into the properties of these isoenzymes. We (18) .
Mitochondria have been shown to contain CPK activity (19) (20) (21) . Jacobus found that Km values for this mitochondrial CPK were lower than for cytoplasmic CPK (21) . Further investigations are required to establish the importance in the living cell of the kinetic differences between the CPK isoenzymes.
In this study the practical use of the differences in enzyme kinetics of the isoenzymes is demonstrated by the establishment of a method for the detection of the MB isoenzyme in the blood after an acute myocardial infarction. This method makes it possible to distinguish elevations in total CPK due to myocardial damage (MB isoenzyme) from elevations caused by muscular trauma, for example, after intramuscular injections or surgery. The rise in the serum level of the MB isoenzyme parallels the elevation in total serum CPK (Fig. 5 ) and a rapid drop is seen once the peak is reached.
It can be seen that MB activity always is under 30% of total CPK activity, in accordance with data obtained with the electrophoresis technique (7) (8) (9) . Human myocardial tissue contains about 30% MB isoenzyme (6) and this study thus shows that the necrotic tissue probably releases both MM and MB CPK at the same rate and to the same extent. More extensive studies will be necessary to establish the usefulness of MB CPK isoenzyme for quantitative studies after acute myocardial infarction.
In conclusion, this rapid, kinetic assay for CPK using luciferase provides information on the behavior of the CPK isoenzymes and is of practical use in the differential diagnosis of patients with an elevated total serum CPK activity.
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